Annexon appoints Mark Blumenkranz to board as Muneer Satter resigns
On August 10, 2026, Annexon appointed retinal surgeon Mark S. Blumenkranz, M.D., M.S.S., to its board of directors, effective immediately. The appointment followed the resignation of director Muneer Satter, who also left the audit committee and stepped down as chair of the nominating committee, and the filing states his resignation was not due to any disagreement with the company. The filing reports no financial results; for shareholders, the change concerns board composition and director pay terms.
Key points
- Mark S. Blumenkranz, M.D., M.S.S., joined the board effective August 10, 2026, as a Class II director with a term expiring at the 2028 annual meeting, and was also appointed to the Audit Committee and Science and Technology committee.
- Muneer Satter resigned from the board, the Audit Committee, and as chair of the Nominating Committee; the company said he served more than eleven years and joined the board in 2015.
- Dr. Blumenkranz receives a $40,000 annual retainer, an annual option grant of 65,000 shares, and a 175,000-share stock option granted in lieu of the standard initial grant.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.